MONITORING THE COMPARATIVE SAFETY OF SGLT2I VS GLP-1 RA IN OLDER ADULTS WITH TYPE 2 DIABETES BY FRAILTY STATUS

被引：0
|
作者：
Kutz, Alexander [1 ]
Patorno, Elisabetta [2 ,3 ]
Gopalakrishnan, Chandrasekar [2 ,3 ]
Kim, Dae [4 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Boston, MA USA
[3] Harvard Med Sch, Boston, MA 02115 USA
[4] Hebrew SeniorLife, Boston, MA USA
来源：
INNOVATION IN AGING | 2021年 / 5卷
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
引用
收藏
页码：208 / 208
页数：1
相关论文
共 50 条
  • [1] Early combination therapy with SGLT2i and GLP-1 RA or dual GIP/GLP-1 RA in type 2 diabetes
    Vale, Catarina
    Lourenco, Ines Mariana
    Jordan, Gabriela
    Golovaty, Ilya
    Torres, Hugo
    Moin, Tannaz
    Buysschaert, Martin
    Neves, Joao Sergio
    Bergman, Michael
    DIABETES OBESITY & METABOLISM, 2024,
  • [2] Comparative Safety and Effectiveness of GLP-1RA and SGLT2i Use in Adults with Type 2 Diabetes in US Clinical Practice
    Hoffman, Sarah R.
    Lanes, Stephan
    Quimbo, Tracey
    Papazian, Aanahit
    White, Jeff
    Fisher, Vicki
    Cziraky, Mark J.
    Crowley, Matthew J.
    Willey, Vincent
    DIABETES, 2024, 73
  • [3] Benefit of dual therapy with GLP-1 RA and SGLT2i on renal outcomes in type 2 diabetes
    Clemmensen, K. K. B.
    Zareini, B.
    Gerds, T.
    Sorensen, K. K.
    Kvist, K.
    David, J. -P.
    Torp-Pedersen, C.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S29 - S29
  • [4] Benefit of Dual Therapy with GLP-1 RA and SGLT2i on Cardiovascular Outcomes in Type 2 Diabetes
    Zareini, Bochra
    Gerds, Thomas A.
    Sorensen, Kathrine K.
    Clemmensen, Kim K. B.
    Kvist, Kajsa
    David, Jens-Peter
    Torp-Pedersen, Christian
    DIABETES, 2023, 72
  • [5] Benefit of dual therapy with GLP-1 RA and SGLT2i on cardiovascular outcomes in type 2 diabetes
    Zareini, B.
    Gerds, T.
    Sorensen, K. K.
    Clemmensen, K. K. B.
    Kvist, K.
    David, J. -P.
    Torp-Pedersen, C.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S30 - S30
  • [6] Benefit of Dual Therapy with GLP-1 RA and SGLT2i on Renal Outcomes in Type 2 Diabetes
    Zareini, Bochra
    Gerds, Thomas A.
    Sorensen, Kathrine K.
    Clemmensen, Kim K. B.
    Kvist, Kajsa
    David, Jens-Peter
    Torp-Pedersen, Christian
    DIABETES, 2023, 72
  • [7] Risk-Benefit of SGLT2 Inhibitors (SGLT2i) vs. GLP-1 Receptor Agonists (GLP-1RA) in Routine Care of Older Adults
    Patorno, Elisabetta
    Kim, Dae H.
    Pawar, Ajinkya
    Schneeweiss, Sebastian
    Glynn, Robert J.
    Munshi, Medha
    Bessette, Lily G.
    Kim, Seoyoung C.
    DIABETES, 2019, 68
  • [8] Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes
    Limonte, Christine P.
    Hall, Yoshio N.
    Trikudanathan, Subbulaxmi
    Tuttle, Katherine R.
    Hirsch, Irl B.
    de Boer, Ian H.
    Zelnick, Leila R.
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2022, 36 (06)
  • [9] Prevalence of SGLT2i and GLP1RA Use among US Adults with Type 2 Diabetes
    Limonte, Christine
    Hall, Yoshio
    Trikudanathan, Subbulaxmi
    Tuttle, Katherine R.
    Hirsch, Irl B.
    De Boer, Ian
    Zelnick, Leila
    DIABETES, 2022, 71
  • [10] Initiation of SGLT2i vs GLP1-RA and incidence of AKI in persons with type 2 diabetes mellitus
    Jensen, Simon Kok
    Heide-Jorgensen, Uffe
    Andersen, Ina Trolle
    Thomsen, Reimar
    Christiansen, Christian Fynbo
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I197 - I198
12345